CASI Pharmaceuticals, Inc.
CASI
$0.94
$0.010.88%
NASDAQ
| 09/30/2025 | 03/31/2025 | 12/31/2024 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.08M | 6.24M | 13.36M | 13.36M | 7.79M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.08M | 6.24M | 13.36M | 13.36M | 7.79M |
| Cost of Revenue | 2.37M | 2.62M | 10.13M | 10.13M | 3.75M |
| Gross Profit | 706.00K | 3.62M | 3.23M | 3.23M | 4.05M |
| SG&A Expenses | 9.54M | 11.92M | 11.92M | 11.92M | 10.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -5.00K | -2.00K | -2.00K | -- |
| Total Operating Expenses | 13.32M | 16.47M | 25.71M | 25.71M | 15.88M |
| Operating Income | -10.24M | -10.23M | -12.35M | -12.35M | -8.09M |
| Income Before Tax | -10.88M | -10.75M | -14.37M | -14.37M | -8.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.88M | -10.75M | -14.37M | -14.37M | -8.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.88M | -10.75M | -14.37M | -14.37M | -8.40M |
| EBIT | -10.24M | -10.23M | -12.35M | -12.35M | -8.09M |
| EBITDA | -9.66M | -9.65M | -11.77M | -11.77M | -7.15M |
| EPS Basic | -0.68 | -0.69 | -0.75 | -0.75 | -0.55 |
| Normalized Basic EPS | -0.42 | -0.42 | -0.40 | -0.40 | -0.39 |
| EPS Diluted | -0.68 | -0.69 | -0.75 | -0.75 | -0.55 |
| Normalized Diluted EPS | -0.42 | -0.42 | -0.40 | -0.40 | -0.39 |
| Average Basic Shares Outstanding | 16.05M | 15.49M | 19.15M | 19.15M | 15.29M |
| Average Diluted Shares Outstanding | 16.05M | 15.49M | 19.15M | 19.15M | 15.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |